BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1464545)

  • 1. [Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].
    Haefliger JM
    Helv Chir Acta; 1992 Oct; 59(3):477-83. PubMed ID: 1464545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Jurincic CD; Horlbeck R; Klippel KF
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):21-5. PubMed ID: 1835139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
    Lunglmayr G
    Prog Clin Biol Res; 1989; 303():145-51. PubMed ID: 2528737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
    Pummer K
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):26-8. PubMed ID: 1948120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Oneto F; Martorana G; Giuliani L; Delli Ponti U; Petracco S; Cortellini P
    Eur Urol; 1990; 18 Suppl 3():48-53. PubMed ID: 2151277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group.
    Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP; Sotarauta M
    Cancer; 1993 Dec; 72(12 Suppl):3878-9. PubMed ID: 8252508
    [No Abstract]   [Full Text] [Related]  

  • 9. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
    Tyrrell CJ; Altwein JE; Klippel F; Jurincic-Winkler C; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
    Eur Urol; 2000 Feb; 37(2):205-11. PubMed ID: 10705200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
    Wirth MP; Weissbach L; Marx FJ; Heckl W; Jellinghaus W; Riedmiller H; Noack B; Hinke A; Froehner M
    Eur Urol; 2004 Mar; 45(3):267-70; discussion 270. PubMed ID: 15036669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
    Di Silverio F; Serio M; Costantini A
    J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
    [No Abstract]   [Full Text] [Related]  

  • 15. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
    Iversen P
    Eur Urol; 1990; 18 Suppl 3():41-4. PubMed ID: 2151275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.
    Lee F; Bahn DK; McHugh TA; Kumar AA; Badalament RA
    Anticancer Res; 1997; 17(3A):1511-5. PubMed ID: 9179188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total androgen ablation: European experience. The EORTC GU Group.
    Denis L; Smith P; Carneiro de Moura JL; Newling D; Bono A; Keuppens F; Mahler C; Robinson M; Sylvester R; De Pauw M
    Urol Clin North Am; 1991 Feb; 18(1):65-73. PubMed ID: 1825144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
    J Urol; 1991 Nov; 146(5):1321-6. PubMed ID: 1834864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
    Iversen P; Christensen MG; Friis E; Hornbøl P; Hvidt V; Iversen HG; Klarskov P; Krarup T; Lund F; Mogensen P
    Cancer; 1990 Sep; 66(5 Suppl):1058-66. PubMed ID: 2144207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.